[Corrected, 9/29/16, 4:24 p.m. See below.] Cancer immunotherapy has captured the medical world’s attention, knocking out a few types of cancer in a small portion of the most desperate patients. But it has bumped into many limitations. Researcher Wendell Lim (pictured) and his lab mates at the University of California, San Francisco, believe they can … Continue reading “Will Programmable Immune “Cellbots” Be the Next Weapon Against Cancer?”
Category: Boston
Genocea Touts Early Look at Placebo-Controlled Herpes Vaccine Study
To date, the studies Genocea Biosciences has run have not made clear how much better its experimental genital herpes vaccine is than a placebo at treating patients with the infection. Genocea is touting new results today that bolster its case for the vaccine, but which still leave some questions for the company to answer going … Continue reading “Genocea Touts Early Look at Placebo-Controlled Herpes Vaccine Study”
Ginkgo Builds Out Robot Labs as Microbe Design Business Grows: Photos
If Ginkgo Bioworks has its way, robots and software will someday handle most of the genetic engineering work currently performed by scientists sitting at lab benches. Ginkgo is contributing to that shift. Today the synthetic biology company announced an expansion of its headquarters in Boston’s Seaport neighborhood, including a second, larger lab space for designing … Continue reading “Ginkgo Builds Out Robot Labs as Microbe Design Business Grows: Photos”
Lose It’s New Photo Tool Turns Your Food Porn Into Calorie Tracker
Success in the hyper-competitive mobile app industry takes endurance. App makers jockey for a coveted spot on our devices’ tiny screens, but few manage to keep our attention over the long haul. One of those rare app companies with staying power is Boston-based FitNow, parent company of the diet and exercise-tracking app Lose It. It … Continue reading “Lose It’s New Photo Tool Turns Your Food Porn Into Calorie Tracker”
Gene Editing, Precision Medicine & More at Disruptors on Oct. 20
Xconomy has brought together some of Boston’s top biotech founders, investors, and leaders for an evening of candid and interactive chats for our latest version of “Boston’s Life Science Disruptors.” On Oct. 20 at the Koch Institute for Integrative Cancer Research at MIT, you’ll hear how these industry leaders are transforming drug development, tackling some … Continue reading “Gene Editing, Precision Medicine & More at Disruptors on Oct. 20”
Eleven Biotherapeutics Receives $13,525,262 New Funding Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a2a7c53d-f280-4009-8e14-12260b41038d Date 9/29/2016 Company Name Eleven Biotherapeutics Mailing Address 215 First Street Cambridge, MA 02142 USA Company Description Eleven Biotherapeutics is focused on developing innovative protein-based therapeutics to improve human health and treat diseases. Website http://www.elevenbio.com Transaction Type Venture Equity Transaction Amount $13,525,262 Transaction Round Undisclosed Proceeds Purposes Proceeds purposes were not … Continue reading “Eleven Biotherapeutics Receives $13,525,262 New Funding Round”
Intra-Cellular Shares Sink As Schizophrenia Drug Flunks Final Test
[Updated 9/29/16, see below] Several promising antipsychotic drugs have made it to late-stage clinical trials only to come up short. Today, you can add an experimental treatment from Intra-Cellular Therapies to the list. Shares of New York-based Intra-Cellular (NASDAQ: [[ticker;ITCI]]) cratered late Wednesday, falling more than 67 percent in after-hours trading after the company disclosed … Continue reading “Intra-Cellular Shares Sink As Schizophrenia Drug Flunks Final Test”
Bio Execs Talk Patient Advocacy, Duchenne Approval at BioForward Panel
Janet Woodcock, the top drug evaluator at the FDA, was the driving force behind the FDA’s recent decision to approve eteplirsen (Exondys 51), a drug for patients with Duchenne muscular dystrophy from Cambridge, MA-based Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]). The decision was controversial: Many FDA scientists didn’t want to approve eteplirsen. They didn’t want to lower the … Continue reading “Bio Execs Talk Patient Advocacy, Duchenne Approval at BioForward Panel”
Avecto Expands in Boston as Endpoint Security Gets More Crowded
Earlier this year, Xconomy compiled a list and map of cybersecurity organizations in the Boston area and found 60-plus companies. One that we missed was Avecto, a U.K.-based endpoint security software firm that opened a Massachusetts outpost in 2009, a year after the company was founded. Now Avecto is drawing more attention, both locally and … Continue reading “Avecto Expands in Boston as Endpoint Security Gets More Crowded”
Constellation Pharmaceuticals Lands $24,298,209 New Financing Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b71a175b-21d4-4a6e-8a19-23b367a392fb Date 9/28/2016 Company Name Constellation Pharmaceuticals Mailing Address 215 First Street Cambridge, MA 02142 USA Company Description Constellation Pharmaceuticals is the leading biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of epigenetics Website http://www.constellationpharma.com Transaction Type Venture Equity Transaction Amount $24,298,209 Transaction Round Undisclosed Proceeds Purposes … Continue reading “Constellation Pharmaceuticals Lands $24,298,209 New Financing Round”
Bayer Exec Dable Takes Reins at Acceleron as Knopf Retires
John Knopf is retiring as the president and CEO of Cambridge, MA-based Acceleron Pharma (NASDAQ: [[ticker:XLRN]]). Knopf, one of the early scientists at the Genetics Institute, co-founded Acceleron in 2003 and took it public in 2013. Bayer veteran Habib Dable, who most recently headed the company’s U.S. pharmaceuticals operations, will take over for Knopf on … Continue reading “Bayer Exec Dable Takes Reins at Acceleron as Knopf Retires”
MIT Accelerator STEX25 Launches With Five Boston-Area Startups
There’s a new startup accelerator program at MIT. This one is pretty different from what you might be expecting. The program, called STEX25, is being run by MIT’s Industrial Liaison Program as part of its Startup Exchange (STEX). The latter has been around for about two years, and its goal is to connect big companies … Continue reading “MIT Accelerator STEX25 Launches With Five Boston-Area Startups”
New Rockefeller Prez Takes Stock of “Wildly Underdeveloped” NY Bio Scene
As the child of a military physicist, Richard Lifton was forced to move around a lot, from Washington, DC, to Albuquerque, New Mexico, to Ankara, Turkey. As an adult he settled in Connecticut, where he became a renowned geneticist at Yale University. Now he’s on the move again, relocating to New York, where he faces … Continue reading “New Rockefeller Prez Takes Stock of “Wildly Underdeveloped” NY Bio Scene”
Neon Therapeutics Taps Novartis Oncology Exec O’Dowd As CEO
Hugh O’Dowd has been named CEO of Cambridge, MA-based immuno-oncology startup Neon Therapeutics, replacing interim CEO and Third Rock Ventures partner Cary Pfeffer. O’Dowd is joining Neon after a more than 20-year stint at Novartis, where he helped commercialize many of the Swiss pharma giant’s cancer drugs, among them imatinib (Gleevec).
Circulation, Uber Team Up to Get Patients to Doctor’s Appointments
Healthcare providers are starting to embrace consumer technologies, and Boston has emerged as one of the hubs of experimentation. The latest example is Circulation, a startup founded last year and partly incubated at Boston Children’s Hospital. The new venture makes software that manages non-emergency medical transportation for patients, primarily those who are elderly, disabled, or … Continue reading “Circulation, Uber Team Up to Get Patients to Doctor’s Appointments”
Podium Data Receives $9,500,000 New Financing
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a73e3f31-a12b-4bb9-b511-4051b67fad45 Date 9/27/2016 Company Name Podium Data Mailing Address 126 Merrimack Street Lowell, MA 01852 USA Company Description Podium Data is empowering the agile enterprise by radically simplifying and improving how organizations manage, prepare and deliver critical information to the business. Website http://www.podiumdata.com Transaction Type Venture Equity Transaction Amount $9,500,000 Transaction Round … Continue reading “Podium Data Receives $9,500,000 New Financing”
SciAps Obtains $1,593,079 New Funding Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=358c8ccf-6164-4e72-bea0-e735e3c95eb8 Date 9/27/2016 Company Name SciAps Mailing Address 2 Constitution Way Woburn, MA 01801 USA Company Description SciAps, Inc., is a Boston-based instrumentation company specializing in portable analytical instruments. Our mission is to provide durable, field-tested, portable instruments to identify any compound, any mineral, any element — anyplace on the planet. Website … Continue reading “SciAps Obtains $1,593,079 New Funding Round”
Podium Data Downloads $9.5M to Help Businesses Manage, Crunch Data
Software companies have talked for years about making tools for deep data analysis simple enough for most business users, not just seasoned programmers. There are signs those capabilities are materializing—or at least evolving. The latest example is Podium Data, a Lowell, MA-based startup that today announced it raised a $9.5 million Series A round led … Continue reading “Podium Data Downloads $9.5M to Help Businesses Manage, Crunch Data”
EpiEP Receives $4,817,577 New Funding Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3657cae0-3573-468a-a4f1-4e0830605384 Date 9/26/2016 Company Name EpiEP Mailing Address 142 Temple Street New Haven, CT 06510 USA Company Description The real-time guidance and confirmation capability of the EpiAccess™ system are based on both disposable and hardware components. The disposable is an access needle that is used to provide single-use access to the pericardial … Continue reading “EpiEP Receives $4,817,577 New Funding Round”
Bio Roundup: Mylan Grilled, Duchenne Kids Thrilled, Zuck-Chan & More
Another biopharma executive went before Congress to explain drug price hikes. Unlike Martin Shkreli, Mylan CEO Heather Bresch actually answered questions. Taking heat over the EpiPen scandal, she tried to stick to her script, getting testy when legislators brought up a USA Today story about her mother helping market the life-saving anti-allergy injection to schools. … Continue reading “Bio Roundup: Mylan Grilled, Duchenne Kids Thrilled, Zuck-Chan & More”
Tech Transforms the Election Experience, From VR to Voter Registration
My friend Eileen and I are planning to “phone-watch” the first presidential debate together on Monday. Just by calling her number in Louisiana from my couch in the Bay Area, I’ll hear hilarious commentary on the Clinton-Trump exchange from Eileen, a terrific reporter who’s wittier than most standup comics. I found another name for this … Continue reading “Tech Transforms the Election Experience, From VR to Voter Registration”
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug
Kathryn Wagner treats boys with Duchenne muscular dystrophy, a rare and fatal genetic disease. She thinks the first drug ever approved to treat Duchenne is “horrendously expensive,” and she’s not comfortable with the data that the FDA said was good enough to merit the approval, which was announced with great controversy this week. But Wagner … Continue reading “Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug”
Pillar Hires Hodges as Boston VCs Build Community, Boost Diversity
It’s been a dynamic year for the Boston venture capital scene. Several new tech-focused funds have launched, some putting new spins on the traditional VC model. And, it’s worth noting, the firms are assembling diverse leadership teams. The latest example comes from Pillar, which today announced a new partner, Sarah Hodges. Hodges (pictured above) previously … Continue reading “Pillar Hires Hodges as Boston VCs Build Community, Boost Diversity”
Talk Bio Diversity With Sato, McGuire at Disruptors on Oct. 20
Gender diversity, or rather the lack of it, remains a problem in biotech board rooms, C-suites, and venture firms. As Polaris Partners general partner and co-founder Terry McGuire wrote in a recent op-ed, quite simply, “we need to do better.” McGuire will join Vicki Sato—a professor of management practice at Harvard University and a former … Continue reading “Talk Bio Diversity With Sato, McGuire at Disruptors on Oct. 20”
When Self-Driving Cars Turn Corner, Other Autos Become Irrelevant
Austin—Autonomous cars are coming. How quickly they take over the automobile market will largely depend on how soon consumers are willing to trust the cars, governments are able to manage the sector, and insurers are able to assess the risk, says Peter Stone, a professor who works in the artificial intelligence laboratory at the University … Continue reading “When Self-Driving Cars Turn Corner, Other Autos Become Irrelevant”
Eleven Bio Buys Viventia, Rebrands as Cancer Drug Developer
Eleven Biotherapeutics became an eye-disease company several years ago, a move that allowed it to go public, raise a bunch of money, and get an eye drug all the way to a pair of late-stage clinical trials. Both studies failed, however, which left the Cambridge, MA, company searching for a new direction—which today has been … Continue reading “Eleven Bio Buys Viventia, Rebrands as Cancer Drug Developer”
Announcing Xconomy’s Agtech and Food Channel
A core tenet of Xconomy—and the reason behind our broad coverage across information technology, life sciences, energy, and more—is that the most interesting and important innovations often arise from the intersection of different disciplines. One of the most important intersections today is between agriculture, the life sciences, and information technology—as evidenced by the growing field … Continue reading “Announcing Xconomy’s Agtech and Food Channel”
SproutsIO Launches Microfarming Device as Indoor Gardens Germinate
The distance from farm to table is now just a few feet, thanks to new systems that allow people to grow food in their kitchen or living room. Last fall, Xconomy covered the launch of a Kickstarter crowdfunding campaign for Somerville, MA-based Grove, a startup out of MIT that developed a product that enables consumers … Continue reading “SproutsIO Launches Microfarming Device as Indoor Gardens Germinate”
Skedaddle Receives $2,100,000 New Funding Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=09767297-94a1-4ee0-bcb1-50e9292cbf65 Date 9/21/2016 Company Name Skedaddle Mailing Address 745 Atlantic Ave. Boston, MA 02111 USA Company Description Skedaddle is reinventing mobility beyond city limits. Moving within city limits is now inexpensive and efficient, yet reaching destinations outside cities is still costly and inconvenient. Website http://www.letskedaddle.com Transaction Type Venture Equity Transaction Amount $2,100,000 … Continue reading “Skedaddle Receives $2,100,000 New Funding Round”
Mautic Obtains $5,000,000 Series A Funding Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=5e36571e-afdb-4d02-92a1-f08bb09d6bd6 Date 9/21/2016 Company Name Mautic Mailing Address 53 State Street 10th Floor Boston, MA 02109 USA Company Description Mautic is what happens when passionate people believe there’s a better way. We began with a singular focus, community. We’re all part of a community that is passionate about what we do. A … Continue reading “Mautic Obtains $5,000,000 Series A Funding Round”
With Tobira Deal, Allergan Keeps Shopping For “Questionable” Assets
[Updated 9/20/16, 4:45 p.m. See below.] Since its mega-merger with drug giant Pfizer (NYSE: [[ticker:PFE]]) fell apart, Allergan has been on an acquisition spree of its own. Its latest purchase has the highest profile—and highest premium—of the lot. Allergan (NYSE: [[ticker:AGN]]) said today it is paying up to $1.7 billion for Tobira Therapeutics (NASDAQ: [[ticker:TBRA]]), … Continue reading “With Tobira Deal, Allergan Keeps Shopping For “Questionable” Assets”
Ultimaker Pushes 3D Printers in U.S. With Help of Former Z Corp Exec
The dream of putting a desktop 3D printer in every home hasn’t materialized, despite a lot of hype, and it might still be years away—if it comes at all. “I don’t know if it’s dead as an idea,” says John Kawola, a Boston-based executive with Dutch 3D printing company Ultimaker. “But we don’t spend any … Continue reading “Ultimaker Pushes 3D Printers in U.S. With Help of Former Z Corp Exec”
Pharmaceutical Price Controls Might Be Closer Than You Think
Amid the hue and cry over the Mylan EpiPen pricing debacle, Hillary Clinton unveiled her “Plan to Respond to Unjustified Price Hikes for Long-Available Drugs.” Clinton’s plan calls for “dedicated oversight to protect consumers.” To that end she would “convene representatives of federal agencies…to create a dedicated group charged with protecting consumers from outlier price … Continue reading “Pharmaceutical Price Controls Might Be Closer Than You Think”
Drive Time Metrics Secures $2,100,000 Seed Financing
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=640564aa-b3ee-473f-aab2-b61f3b4ea62d Date 9/20/2016 Company Name Drive Time Metrics Mailing Address 402 Angell Street Providence, RI 02906 USA Company Description Drive Time Metrics is focused on developing innovative new revenue streams from connected car data to help automotive OEMs monetize their connected vehicle platforms. Website http://www.drivetimemetrics.com Transaction Type Venture Equity Transaction Amount $2,100,000 … Continue reading “Drive Time Metrics Secures $2,100,000 Seed Financing”
Sarepta Prices $300K Duchenne Drug As FDA Rift Emerges Over Approval
The FDA approved Monday the first drug ever for Duchenne muscular dystrophy, but only after the commissioner had to settle a high-stakes dispute between powerful agency scientists. Prominent members of the FDA’s drug-review staff, fearful of setting a precedent for the regulation of drugs for rare diseases, voted to reject eteplirsen (Exondys 51), from Cambridge, … Continue reading “Sarepta Prices $300K Duchenne Drug As FDA Rift Emerges Over Approval”
After $70M Boston Scientific Deal, CeloNova CEO Heads to Nonprofit
San Antonio — Martin Landon, a long-time San Antonio life sciences executive, has left the chief executive role at medical device maker CeloNova Biosciences a year after selling a portion of the business to Boston Scientific for $70 million. Landon has taken a new job as the CEO of nonprofit BioBridge Global. San Antonio-based BioBridge … Continue reading “After $70M Boston Scientific Deal, CeloNova CEO Heads to Nonprofit”
FourPlay Football Offers Fantasy Pick ‘Em Leagues with a Twist
I first started playing fantasy football in 1998, before Yahoo leagues, or channels wholly dedicated to jumping from game to game to show potential scoring drives from the end zone, or multiple talking heads earnestly spouting off about a made-up game each week. Back then, when one still needed a dial-up modem to access the … Continue reading “FourPlay Football Offers Fantasy Pick ‘Em Leagues with a Twist”
After New Data, FDA Bucks Advisory Panel, Approves Sarepta’s Duchenne Drug
[Updated 9/19/16, 12:42 p.m. See below.] In a decision that could have myriad implications for both the pharmaceutical industry and patients with Duchenne muscular dystrophy, the FDA today approved a drug called eteplirsen from Cambridge, MA-based Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]). With the FDA nod, eteplirsen has become the first drug ever approved for Duchenne, a … Continue reading “After New Data, FDA Bucks Advisory Panel, Approves Sarepta’s Duchenne Drug”
With $163M Deal, Tarveda Revives Synta Pharma’s Cancer Drug Work
Earlier this year, Blend Therapeutics changed its name to Tarveda Therapeutics and spun what used to be its lead drug into a separate company, the latest steps in a strategic overhaul. The wheeling and dealing continued this morning for the Watertown, MA, company, which has cut a deal with Madrigal Pharmaceuticals—the firm that recently merged … Continue reading “With $163M Deal, Tarveda Revives Synta Pharma’s Cancer Drug Work”
Workforce Trends, Economy, & More: Q&A With Alexandria’s Joel Marcus
Think “innovation” and you might picture some scrappy entrepreneurs toiling away in a kitchen or garage, hoping the landlord doesn’t notice what they’re up to. But the reality is that turning science into big business often requires far more sophisticated infrastructure—and the landlord who provides that infrastructure sometimes has one of the best windows into … Continue reading “Workforce Trends, Economy, & More: Q&A With Alexandria’s Joel Marcus”
Boston Tech Watch: Driverless Cars, Stealthy Startups, Deals & More
Fall’s arrival has brought with it a ton of tech news. Here are the latest headlines from the Boston area, spanning self-driving cars, a flurry of startup funding deals, a lawsuit over 3D printer patents, and more. Read on for details. —Self-driving cars will soon be tested on Boston streets as part of a year-long … Continue reading “Boston Tech Watch: Driverless Cars, Stealthy Startups, Deals & More”
Survey: Tech Startup Leaders Want Diversity, Not Sure How to Reach It
Tech startup leaders “want to create an inclusive and diverse workforce, but many simply don’t know what to do to build inclusive teams.” That’s how Techstars co-founder and co-CEO David Cohen put it in a blog post earlier this week summarizing the results of a survey of 680 startup founders and top executives, mainly of … Continue reading “Survey: Tech Startup Leaders Want Diversity, Not Sure How to Reach It”
Everbridge Stock Jumps Over 20 Percent in Wall Street Debut
Everbridge’s first day as a publicly traded company is in the books: Wall Street investors bid up its stock by more than 20 percent. The Burlington, MA-based company (NASDAQ: [[ticker:EVBG]]) closed at $15.25 per share. That’s 27 percent higher than the company’s initial $12 pricing last night, and it’s nearly 24 percent above the $12.30 … Continue reading “Everbridge Stock Jumps Over 20 Percent in Wall Street Debut”
Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More
Across the nation, and even looking back into the past, health was in the headlines this week. Our presidential candidates were either recovering from pneumonia or talking up their health records. New documents came to light that showed the sugar industry paid for studies downplaying the ties between sugar and heart disease. And the drug-price … Continue reading “Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More”
What Startups Can Do About Cyber Attacks
A cybersecurity report by Ponemon Institute, in association with Keeper Security, found that in the 12 months leading up to June 2016, 55 percent of small and medium-sized businesses (SMBs) experienced a cyber attack, while 50 percent encountered data breaches involving customer and employee information. These statistics belie the common notion that cybercriminals attack only … Continue reading “What Startups Can Do About Cyber Attacks”
BitSight Lands $40,000,000 Series C Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4f2cae52-5ac6-4b7d-bd53-0b0900964e70 Date 9/16/2016 Company Name BitSight Mailing Address 125 Cambridge Park Drive Cambridge, MA 02140 USA Company Description BitSight is the only security ratings platform that is proven to indicate the risk of a publicly disclosed data breach. Website http://www.bitsighttech.com Transaction Type Venture Equity Transaction Amount $40,000,000 Transaction Round Series C Proceeds … Continue reading “BitSight Lands $40,000,000 Series C Round”
Sofregen Medical Lands $6,200,000 Series A Financing
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=39acf449-8dc4-4771-92ab-3c302c9a70d5 Date 9/16/2016 Company Name Sofregen Medical Mailing Address 200 Boston Ave. Medford, MA 02155 USA Company Description Founded in 2014 to advance technology developed at Tufts University and the University of Pittsburgh, Sofregen is a pioneer in the use of silk, nature’s healing fiber, in a variety of forms to help … Continue reading “Sofregen Medical Lands $6,200,000 Series A Financing”
Intarcia Therapeutics Receives $215,000,000 New Financing
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=633b6c8b-39f2-4de6-970c-62bcac7b39c1 Date 9/16/2016 Company Name Intarcia Therapeutics Mailing Address 155 Seaport Boulevard 11th Floor Boston, MA 02210 USA Company Description Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories. Website http://www.intarcia.com Transaction Type Venture … Continue reading “Intarcia Therapeutics Receives $215,000,000 New Financing”
Promoboxx Obtains $8,200,000 Series A Financing Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=445db780-e2cb-4661-b74d-cbd821797858 Date 9/16/2016 Company Name Promoboxx Mailing Address 500 Harrison Ave. Boston, MA 02118 USA Company Description Promoboxx offers a product that allows manufacturing brands to help their retailers with local online marketing. Previous campaigns included one with Chevy in January, which allowed 6,000 Chevy dealers to share the car maker’s Super … Continue reading “Promoboxx Obtains $8,200,000 Series A Financing Round”
Event Farm Acquires Attend for Undisclosed Sum
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=95fe315c-c53d-43d5-8a91-48bc3be8400b Date 9/16/2016 Company Name Attend Mailing Address 10 Post Office Square Boston, MA 02109 USA Company Description Attend’s Revenue Event Marketing platform empowers your team to create and accelerate sales pipeline with in-person events. Website http://www.attend.com Transaction Type M&A Transaction Amount Undisclosed Transaction Round Proceeds Purposes M&A Terms Financial terms of … Continue reading “Event Farm Acquires Attend for Undisclosed Sum”